Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 /PRNewswire/ ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ... Summary,Although the past decade has ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an ... for patients to self-inject prescription drugs in the large ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... expected to grow to $220B by 2018, according to ... type of injector that does not exist today for ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ... and Pittsburgh markets. Progressive was founded ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 2007 - A new study published,in the ... Neurology indicates,that a treatment from Medtronic, Inc. ... improves their quality of life and is,cost-effective ... of this Medtronic-sponsored study should,expand access to ...
... they are outraged,over recent media coverage about ... treat a hormone deficiency often associated,with aging., ... -- The adult,use of human growth hormone ... recent New,York Times article about the founders ...
Cached Medicine Technology:Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 2Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 3Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 4Doctors Outraged Over Growth Hormone Controversy 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... ... 2009 -- Bariatric Advantage, a Division of Catalina Lifesciences, Inc. Announces The Promotion of ... ... Advantage, a Division of Catalina Lifesciences, Inc. Announces The Promotion of Bret Petkus to ...
... believes more research is needed , WEDNESDAY, Dec. 30 (HealthDay ... to ease hot flashes and other uncomfortable symptoms in women ... the needle treatment may boost the patient,s sex drive and ... shows you that acupuncture is a good option for these ...
... , ALISO VIEJO, Calif., Dec. 30 Valeant Pharmaceuticals International ... Food and Drug Administration (FDA) has accepted for review the ... drug retigabine, a neuronal potassium channel opener for the adjunctive ... addition, the European Medicines Agency (EMEA) confirmed on November 17, ...
... , FORT LAUDERDALE, Fla., Dec. 30 eDiets.com, Inc. ... fitness and healthy lifestyle solutions, today announced that long-time eDiets.com member ... when she went from weighing 326 pounds over two years ago ... PEOPLE,s upcoming January 11th "Half Their Size" issue which will be ...
... , MINNEAPOLIS, Dec. 30 Happy Hour Effect(TM), a ... employment stress and promote work/life balance, is pleased to announce ... in time for our 2010 New Year,s resolutions. ... consists of an easy and fun process that guides users ...
... , ATLANTA, Dec. 30 Martin Luther King Jr. weekend ... Bid Whist Tournament with a Qualifying Tournament and Health Fair in ... 7 NO! Players of Atlanta, the original hosts of the Bid ... in the Black community. The Health Fair, in partnership with local ...
Cached Medicine News:Health News:Bariatric Advantage, a Division of Catalina Lifesciences, Inc. Announces Appointment of Bret Petkus to Vice-President of North American Sales. 2Health News:Acupuncture May Cut Hot Flashes, Boost Sex Drive in Breast Cancer Patients 2Health News:FDA Accepts NDA Filing for Retigabine 2Health News:eDiets.com(R) Member Loses Over 150 lbs, to be Featured in PEOPLE Magazine and on The TODAY Show 2Health News:New Year's Resolutions Just Got Easier - Happy Hour Effect LLC to Launch 'The Happy Hour Effect(TM) Balance Plan' in 2010 2Health News:New Year's Resolutions Just Got Easier - Happy Hour Effect LLC to Launch 'The Happy Hour Effect(TM) Balance Plan' in 2010 3Health News:The Black AIDS Institute Kicks Off Its National Platform to Build Black AIDS Awareness in Atlanta, GA 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: